[Form 4] Teladoc Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 snapshot: Teladoc Health, Inc. (TDOC) disclosed that director Jason Eric Evans converted restricted stock units (RSUs) into 1,016 shares of common stock on 20 June 2025. The transaction was coded “M,” indicating the exercise or conversion of a derivative security.

Following the transaction, Evans’ direct holdings in TDOC increased to 7,113 shares. His remaining unvested/undelivered derivative position stands at 5,082 RSUs. The RSUs originated from a 20 September 2023 grant of 12,195 units that vest one-third after one year and the balance in eight equal quarterly instalments.

No sale of shares was reported and no cash price was listed, implying a cost-free share settlement typical of RSU conversions. The filing contains no information on TDOC’s current operational performance, earnings, or other corporate events.

In sum, the Form 4 records a routine equity settlement that modestly increases insider share ownership but does not represent a market-moving development for Teladoc Health.

Positive

• Director increased direct share ownership by 1,016 shares, which can be viewed as a minor sign of insider alignment.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine RSU conversion; negligible impact on TDOC valuation.

The M-code transaction reflects automatic conversion of vested RSUs into 1,016 shares. Director Jason Evans now holds 7,113 shares and 5,082 RSUs. No shares were sold, so there is no direct sale-signal or liquidity event. Given Teladoc’s ~160 million shares outstanding, the incremental ownership change is <0.01%—far too small to influence float or strategic direction. Investors may view continued share accumulation as marginally positive insider alignment, but the event is operationally routine and offers no insight into current fundamentals or forward outlook. I classify the filing as neutral/not impactful for investment decisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans Jason Eric

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.

155 E 44TH ST, FLOOR 17

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		M		1,016	A	(1)	7,113	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/20/2025		M			1,016	(2)	(2)	Common Stock	1,016	$0	5,082	D

Explanation of Responses:

1. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

2. On September 20, 2023, the reporting person was granted 12,195 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Teladoc Health (TDOC) shares did Jason Evans acquire on 20 June 2025?

1,016 shares of TDOC common stock were acquired via RSU conversion.

What is Jason Evans’ total direct TDOC shareholding after the transaction?

He now directly owns 7,113 TDOC shares.

Did Jason Evans sell any Teladoc Health shares in this Form 4 filing?

No. The filing reports an acquisition only; no shares were sold.

What derivative securities remain after the RSU conversion?

Evans still holds 5,082 restricted stock units that will settle into common shares as they vest.

Is the reported Form 4 transaction considered material to TDOC investors?

Given the small size (<0.01% of shares outstanding), it is generally viewed as not materially impactful.